These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34254894)

  • 21. Vaccine Strategy During the SARS-CoV-2 Pandemic: What School Nurses Need to Know.
    Barnby E; Reynolds M; Gordon J
    NASN Sch Nurse; 2021 Nov; 36(6):316-322. PubMed ID: 34060925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines.
    Hofman K; Shenoy GN; Chak V; Balu-Iyer SV
    Immunol Invest; 2021 Oct; 50(7):743-779. PubMed ID: 33929280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Consolidated recommendations of the Advisory Committee on Vaccines and Immunization Strategies- on prioritizing COVID-19 vaccination].
    Dabanch J; Bastías M; Endeiza ML; Díaz E; Inostroza J; Cerda J; Santillana S; Rodríguez J; González C; Rodríguez M; Pizarro A
    Rev Chilena Infectol; 2021 Apr; 38(2):185-188. PubMed ID: 34184708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Planning for COVID-19 vaccines safety surveillance.
    Kochhar S; Salmon DA
    Vaccine; 2020 Sep; 38(40):6194-6198. PubMed ID: 32684499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein-based nano-vaccines against SARS-CoV-2: Current design strategies and advances of candidate vaccines.
    Wang D; Yuan Y; Liu B; Epstein ND; Yang Y
    Int J Biol Macromol; 2023 May; 236():123979. PubMed ID: 36907305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. People's Willingness to Vaccinate Against COVID-19 Despite Their Safety Concerns: Twitter Poll Analysis.
    Eibensteiner F; Ritschl V; Nawaz FA; Fazel SS; Tsagkaris C; Kulnik ST; Crutzen R; Klager E; Völkl-Kernstock S; Schaden E; Kletecka-Pulker M; Willschke H; Atanasov AG
    J Med Internet Res; 2021 Apr; 23(4):e28973. PubMed ID: 33872185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2: vaccines in the pandemic era.
    Li DD; Li QH
    Mil Med Res; 2021 Jan; 8(1):1. PubMed ID: 33402220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Highlight of severe acute respiratory syndrome coronavirus-2 vaccine development against COVID-19 pandemic.
    Liu CH; Huang HY; Tu YF; Lai WY; Wang CL; Sun JR; Chien Y; Lin TW; Lin YY; Chien CS; Huang CH; Chen YM; Huang PI; Wang FD; Yang YP
    J Chin Med Assoc; 2021 Jan; 84(1):9-13. PubMed ID: 33186212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology.
    Gresham LM; Marzario B; Dutz J; Kirchhof MG
    J Am Acad Dermatol; 2021 Jun; 84(6):1652-1666. PubMed ID: 33482251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On Setting Expectations for a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
    Canaday DH; Gravenstein S
    Clin Infect Dis; 2021 Feb; 72(3):513-514. PubMed ID: 33527123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multisystem Inflammatory Syndrome after SARS-CoV-2 Infection and COVID-19 Vaccination.
    Salzman MB; Huang CW; O'Brien CM; Castillo RD
    Emerg Infect Dis; 2021 Jul; 27(7):1944-1948. PubMed ID: 34034858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development.
    Wang F; Kream RM; Stefano GB
    Med Sci Monit; 2020 May; 26():e924700. PubMed ID: 32366816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targets and strategies for vaccine development against SARS-CoV-2.
    Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR
    Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccination against SARS-CoV-2 and disease enhancement - knowns and unknowns.
    Zellweger RM; Wartel TA; Marks F; Song M; Kim JH
    Expert Rev Vaccines; 2020 Aug; 19(8):691-698. PubMed ID: 32838605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines.
    Flanagan KL; Best E; Crawford NW; Giles M; Koirala A; Macartney K; Russell F; Teh BW; Wen SC
    Front Immunol; 2020; 11():579250. PubMed ID: 33123165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune imprinting and SARS-CoV-2 vaccine design.
    Wheatley AK; Fox A; Tan HX; Juno JA; Davenport MP; Subbarao K; Kent SJ
    Trends Immunol; 2021 Nov; 42(11):956-959. PubMed ID: 34580004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Considerations on vaccines and immunization against COVID-19 for epidemic control in China].
    Zhang Q; Wang FZ; Ma C; An ZJ; Yin ZD
    Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1371-1376. PubMed ID: 34963231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations.
    Sultana J; Mazzaglia G; Luxi N; Cancellieri A; Capuano A; Ferrajolo C; de Waure C; Ferlazzo G; Trifirò G
    Expert Rev Vaccines; 2020 Oct; 19(10):919-936. PubMed ID: 32940090
    [No Abstract]   [Full Text] [Related]  

  • 39. Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2.
    Plotkin SA
    J Pediatric Infect Dis Soc; 2020 Nov; 9(5):517-518. PubMed ID: 32744616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.